Date post: | 24-Nov-2023 |
Category: |
Documents |
Upload: | independent |
View: | 0 times |
Download: | 0 times |
Effect of ionized serum calcium on outcomes in acute kidneyinjury needing renal replacement therapy: Secondary analysis ofthe Acute Renal Failure Trial Network Study
Farsad Afshinnia, MD, MS,Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor VAMedical Center, Michigan
Karen Belanger, MS,University of Michigan, Ann Arbor VA Medical Center, Michigan
Paul M. Palevsky, MD [Chief], andRenal Section, VA Pittsburgh Healthcare System; Professor of Medicine and Clinical &Translational Science, University of Pittsburgh School of Medicine
Eric W. Young, MD, MS [Professor]Medicine, Department of Internal Medicine, Division of Nephrology, University of Michigan, AnnArbor VA Medical Center, Michigan
Farsad Afshinnia: [email protected]; Karen Belanger: [email protected]; Paul M. Palevsky:[email protected]; Eric W. Young: [email protected]
Abstract
Background—Hypocalcemia is very common in critically ill patients. While the effect of
ionized calcium (iCa) on outcome is not well understood, manipulation of iCa in critically ill
patients is a common practice. We analyzed all-cause mortality and several secondary outcomes in
patients with acute kidney injury (AKI) by categories of serum iCa among participants in the
Acute Renal Failure Trial Network (ATN) Study.
Methods—This is a post hoc secondary analysis of the ATN Study which was not preplanned in
the original trial. Risk of mortality and renal recovery by categories of iCa were compared using
multiple fixed and adjusted time-varying Cox regression models. Multiple linear regression
models were used to explore the impact of baseline iCa on days free from ICU and hospital.
Results—A total of 685 patients were included in the analysis. Mean age was 60 (SD=15) years.
There were 502 male patients (73.3%). Sixty-day all-cause mortality was 57.0%, 54.8%, and
54.4%, in patients with an iCa <1, 1–1.14, and ≥1.15 mmol/L, respectively (P=0.87). Mean of
days free from ICU or hospital in all patients and the 28-day renal recovery in survivors to day 28
were not significantly different by categories of iCa. The hazard for death in a fully adjusted time-
varying Cox regression survival model was 1.7 (95% CI: 1.3–2.4) comparing iCa <1 to iCa ≥1.15
mmol/L. No outcome was different for levels of iCa >1 mmol/L.
Corresponding Author: Farsad Afshinnia, Address: 3914 Taubman Center, 1500 E. Medical Center Dr., SPC 5364, Ann Arbor, MI48109-5364, Office: 734-764-3469, Fax: 734-936-9621, [email protected].
NIH Public AccessAuthor ManuscriptRen Fail. Author manuscript; available in PMC 2014 November 01.
Published in final edited form as:Ren Fail. 2013 ; 35(10): 1310–1318. doi:10.3109/0886022X.2013.828258.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Conclusion—Severe hypocalcemia with iCa <1 mmol/L independently predicted mortality in
patients with AKI needing renal replacement therapy.
Keywords
Acute kidney injury; Mortality; Renal replacement therapy; Hypocalcemia; Renal recovery;Length of stay
Introduction
The serum ionized calcium (iCa) is directly associated with smooth muscle and left
ventricular contractility.1–3 These observations have been confirmed in chronic stable
hemodialysis patients4,5 with a mechanistic underpinning6 that has been used to justify
targeting higher serum iCa levels in critically ill patients with multi-organ failure.
Particularly in patients receiving continuous renal replacement therapy, regional citrate
anticoagulation allows targeting a desired serum iCa level through changes in the calcium
and citrate infusion rates. However, the theoretical concept of achieving a better
hemodynamic status in critically ill patients receiving renal replacement therapy by targeting
a high-normal range of iCa is primarily an extrapolation of observations in chronic stable
dialysis patients. In fact there are no randomized controlled clinical trials that show a
survival benefit by targeting a specific level of serum iCa in critically ill patients with acute
kidney injury (AKI). On the other hand, there could even be harm associated with excessive
utilization of calcium supplementation by targeting high-normal or high levels of serum iCa
in AKI including cardiac arrhythmias, metastatic calcification, nephrolithiasis, and renal
tubular acidosis.7–12 This study is aimed to investigate the association between different
levels of serum iCa concentrations with several clinical outcomes including 60-day all-cause
mortality (primary outcome), 28-day renal recovery, days free from the ICU, days free from
the hospital and mean arterial pressure (MAP), in critically ill ICU patients with AKI
needing renal replacement therapy.
Methods
This study is a post hoc secondary analysis of the Acute Renal Failure Trial Network (ATN)
Study. The primary study results have been previously published.13,14 The ATN Study was
a multicenter, randomized, clinical trial aimed at comparing the outcomes of different
intensities of renal replacement therapy in critically ill patients with AKI due to acute
tubular necrosis (ATN), conducted in 27 centers across the United States. Eligible patients
were 18 years of age or older, critically ill with AKI consistent with ATN needing renal
replacement therapy and accompanied by sepsis or failure of at least one non-renal organ
system. After screening, enrolled eligible patients were randomly assigned to two different
intensities of renal replacement therapy using a centralized computer-generated adaptive
randomization scheme. Assigned interventions were delivered for up to 28 days after
randomization or until renal recovery, discharge from the ICU, withdrawal of care, or death.
Patients were followed for up to 60 days to ascertain the primary end point of all-cause
mortality.
Afshinnia et al. Page 2
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
After obtaining local institutional review board approval, we requested and received the
study dataset from the NIDDK central repository. All data files were reviewed and all
patients with valid measurements of serum iCa at baseline were included. Ionized calcium
was categorized to less than 1 mmol/L (severe hypocalcemia), 1 to 1.14 mmol/L (mild
hypocalcemia), and 1.15 mmol/L or more according to existing classification.15 The same
cut-points were applied to categorize iCa in subsequent days, as well as for the classification
of the time-averaged iCa during ICU stay. Pressor support was defined as use of any type of
pressor (epinephrine, norepinephrine, phenylephrine, dopamine, dobutamine, vasopressin) at
any point throughout the study from baseline to post-randomization days of 1 to 14, 21, and
28. Renal recovery among survivors to day 28 was defined as being off dialysis by day 28.
Days free from the ICU/hospital was defined as the number of days from ICU/hospital
discharge until 60 days after randomization or death, whichever occurred first. MAP was
calculated from systolic and diastolic blood pressures throughout the study from baseline to
days 1 to 14, 21 and 28 after randomization. In this cohort 1124 patients were randomized.
Five patients were excluded due to erroneous levels of iCa at baseline and 434 others were
excluded due to unmeasured serum iCa at baseline. The final analysis included 685 patients.
Statistical analysis
Mean ± standard deviation or counts and percentages were used to describe the distribution
of continuous and categorical variables, respectively. Median values and interquartile range
were used when the distribution of variables was skewed. The Chi-square test was used to
compare categorical variables across categories of iCa. Analysis of variance was used to
compare the mean of continuous variables across the categories of iCa. Bonferroni
correction with post hoc analysis was used to identify statistically significant differences
among iCa groups, correcting for multiple measurements. We took two different approaches
to assess mortality and renal recovery outcomes. First, Cox regression survival models were
applied to test the prognostic value of baseline as well as time-varying iCa on 60-day
mortality and 28-day renal recovery. As iCa was measured at irregular intervals and with
various frequencies, the last measured iCa was used and carried forward to next
measurement or to outcome, in the construct of time-varying survival models. The
covariates in the fully adjusted survival models included age, gender, race, baseline
components of ATN study predictive risk model for 60-day mortality16, and time varying
covariates during study including number of pressor agents per day, system Sequential
Organ Failure Assessment (SOFA) scores, MAP, and mechanical ventilation. In an
alternative approach, time-averaged iCa during ICU stay for each patient was calculated
assuming a linear trend between subsequent measurements, weighted by the number of days
between the observations. For example, an iCa of 1.2 mmol/L followed by an iCa of 1.3 in
two days, yields a value of 1.25 mmol/L weighted by two days. The sums of such weighted
values were then divided by the number of days between the first and last measured iCa
during ICU stay to result in the time-averaged iCa for a given individual during the study
period. Then, different subgroups of the time-averaged iCa during ICU stay were used to
compare their mortality odds ratio versus reference category (time-averaged iCa≥1.15
mmol/l), using multiple logistic regression models. To study the effect of the change in iCa
on mortality over time by change from below 1 to ≥1 mmol/L, in addition to testing in Cox
models, we categorized the patients in to four subgroups: A)- patients whose serum iCa
Afshinnia et al. Page 3
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
remained 1 mmol/L or above throughout the study; B)- patients with an initial iCa less than
1 mmol/L but with subsequent levels of ≥1mmol/L; C)- patients with an initial iCa≥1
mmol/L but with subsequent level <1 mmol/L; D)- and patients whose serum iCa remained
<1 mmol/L throughout the study. Then multiple logistic regression models were used to
explore the mortality odds ratio of subgroups versus group A as the reference category.
To test the independent effect of iCa on days-free from the ICU and hospital, multiple linear
regression models with multivariable adjustments were applied. A mixed model with iCa as
a repeated measure was applied to show its variability throughout the study and to test its
independent effect on MAP. The baseline components of ATN Study predictive risk model
for 60-day mortality were imputed by application of highly interrelated variables using
multiple linear regression models. The survival models were calculated with and without
imputation. P values of less than 0.01 for differences in the baseline variables are declared.
Analyses were performed using SAS version 9.2, and SPSS version 20.
Results
Among the 685 patients entered into this study, the mean age was 60 years (SD = 15) and
502 were male (73.3%). The median number of measurements of iCa after randomization
was four with an interquartile range of 2 to 9. As shown in Table 1, there was a graded
increase in proportion of post-surgical AKI from the lowest to the highest category of
baseline iCa (p<0.001). Nephrotoxic ATN had the lowest proportion in the first category as
compared to other categories (p=0.009). There was also a graded decrease in severity of
cardiovascular SOFA score from the lowest to the highest baseline iCa (p=0.002). Other
variables were not significantly different among the categories of baseline iCa. Table 2
shows the management of renal replacement therapy using different modalities of dialysis
by categories of iCa. The delivered KT/V with IHD and the effluent flow with CVVHDF
were not significantly different across the categories of iCa. Figure 1 shows the patterns of
change in level of iCa during the ICU stay by baseline categories of iCa. Overall, mean of
iCa in patients with the baseline iCa< 1 mmol/L increased to more than 1.05 mmol/L after 3
days in survivors to day 3 and beyond.
Table 3 shows that there were no significant differences in the outcomes of 60-day
mortality, days free from ICU or hospital in all patients as well as in 28-day renal recovery
among survivors to day 28 by categories of baseline iCa. Figure 2, panel A (supplement
Table 2) shows the Cox regression survival modeled hazard ratio (HR) of 60-day mortality
by categories of baseline iCa as well as iCa as a time varying variable, with increasing
degrees of adjustment, using iCa ≥ 1.15 mmol/L as the reference group (HR=1).
Accordingly, when categories of iCa at baseline were compared, there was no difference in
the risk of mortality across the categories (Model 1). However, when iCa was entered as a
time-varying variable either in an unadjusted manner (Model 2) or in partially to fully
adjusted models (Models 3 and 4), iCa less than 1 mmol/L as compared to level ≥ 1.15 was
an independent predictor of 60-day all-cause mortality. Similar approach did not show any
difference in outcome of renal recovery by 28 day (panel B, Models 1 to 4, and supplement
Table 2). Similarly, days free from ICU and Hospital were not associated with categories of
serum iCa according to multiple linear regression models (supplement Table 3). Application
Afshinnia et al. Page 4
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
of a mixed model revealed no association between MAP and the level of iCa during ICU
stay (supplement Table 4). Figure 3 shows the adjusted HR of mortality in the lowest versus
the highest category of iCa by clinical subgroups. A low iCa was associated with increased
mortality risk in all subgroups although statistical significance was not reached for age ≤ 60,
black and other races, baseline total SOFA score < 15, Cleveland ICU Acute Renal Failure
score < 13, age adjusted Charlson score < 4, and baseline albumin < 2.3 g/dL.
In an alternative approach baseline characteristics of the patients were compared by
categories of time-averaged iCa during ICU stay (supplement Table 1) which showed no
significant differences in distribution of baseline variables as compared to Table 1. Using
multiple logistic regression analysis, a time-averaged iCa of less than 1 mmol/L, and not iCa
of 1 to 1.14 mmol/L throughout stay in ICU as compared to iCa of 1.15 or above was
associated with higher odds of 60-day mortality in different models from unadjusted to fully
adjusted (supplement Table 5). Similar table shows that the 28-day renal recovery has not
been different by levels of the time-averaged iCa during ICU stay. Supplement Figure 1
shows the change in the level and direction of iCa during the ICU stay by subgroups of
patients defined by iCa trend. Supplement table 6 shows that patients who continued to have
an iCa below 1 mmol/L during ICU stay had a significantly higher odds of 60-day mortality
as compared to those who had iCa above 1 mmol/L, in several unadjusted to fully adjusted
models. Similarly those with a low iCa (<1 mmol/L) who achieved iCa>1 mmol/L in
subsequent days had a mortality similar to patient with iCa>1 mmol/L at all times.
Discussion
In this study, the 60-day all-cause mortality, 28-day renal recovery, days free from ICU and
hospital were not significantly different by the levels of baseline iCa. MAP during ICU stay
was not dependent on absolute values of iCa, and multivariable models did not show any
relationship between iCa with renal recovery, days free from hospital or ICU. However,
survival models using iCa as a time-varying variable suggest that serum iCa<1 mmol/L
compared to iCa≥1.15 mmol/L independently predicts short-term mortality. This is
consistent with results from logistic regression models which have used categories of a time-
averaged iCa during ICU stay.
Chernow et al17 reported a study of 259 ICU patients, finding that those with hypocalcemia
had a higher mortality, a longer duration of stay in the ICU, and higher likelihoods of sepsis,
renal failure and blood transfusion as compared to the normocalcemic group. Desai et a18
studied 108 critically ill patients admitted to the ICU and found mortality rates of 44% in
patients with hypocalcemia compared to 17% in patients without hypocalcemia. In a study
of 199 patients, Zivin et al19 demonstrated that iCa was inversely correlated with the
APACHE score and, therefore, suggested that higher mortality observed with hypocalcemia
might be a reflection of severity of disease. In a larger study from the Helsinki University
Hospital, Hastbacka et al reported the hypocalcemia rate of up to 85% in 993 critically ill
patients defined as iCa less than 1.16 mmol/L.20 Although the investigators showed a higher
risk of mortality among patients with hypocalcemia, hypocalcemia did not appear to be an
independent risk factor for mortality after multivariable adjustment for severity of disease at
baseline as measured by the APACHE score. Their analysis, however, was limited to use of
Afshinnia et al. Page 5
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
a single baseline measurement of iCa per patient and therefore did not take into account the
impact of changes in serum iCa over time or the duration of time at each level of iCa. In a
cohort of 7024 critically ill patients from four medical centers, Egi et al15 used a time
weighted approach to account for the level of iCa during critical care and found a graded
inverse relationship between mortality and serum iCa even after multivariable adjustments.
This approach has allowed the investigators to capture worse outcome attributable to
changes of iCa over time. In our study, other than use of time-varying Cox survival models,
we also calculated a time-averaged iCa during ICU stay and compared risk of mortality
across its categories using logistic regression models, and found similar higher mortality risk
with iCa<1 mmol (Supplement table 5). Similar results from the two approaches suggest that
the latter has been able to capture the higher mortality attributed to change of iCa over time,
a phenomenon which was captured similarly with Cox models. Our findings are in
agreement with previous observations15,17–22 and can be considered as reconciling the
seemingly contradictory results of the studies by Hastbacka and Egi. Although the mortality
was not different by baseline level of iCa after adjusting for severity of disease, the time-
varying analysis accounting for change of iCa throughout ICU stay unmasked its prognostic
value to predict mortality. The reason that a time-varying Cox model and not the fixed
model has unmasked the prognostic value of iCa is that a significant number of patients with
a baseline iCa of above 1 mmol/L who subsequently died, dropped their iCa to a level of <1
mmol/L in later days prior to their death. On the other hand, significant number of other
patients with iCa<1 mmol/L at baseline who eventually survived, improved their iCa to a
level of ≥1 mmol/L in subsequent days, a phenomenon which could be unmasked by
application of a time-varying approach taking into account change of iCa in subsequent
days. Consistent with these findings, in an alternative approach, patients who continuously
had iCa<1 mmol/L throughout ICU stay had a significantly higher mortality odds ratio (OR)
as compared to patients who kept their iCa≥1 mmol/L at all time, while those severely
hypocalcemic patients at baseline with increased iCa to ≥1mmo/L in subsequent days didn’t
have different mortality OR as compared to those with iCa≥1 mmol/L at all times
(Supplement table 6).
Hypocalcemia is a common electrolyte abnormality in critically ill patients and in ICU
settings17,19,20. Although the etiology of hypocalcemia is unclear in the majority of critically
ill patients, proposed mechanisms include the effect of sepsis, impairment of parathyroid
hormone secretion, resistance of end-organs to the function of parathyroid hormone,
alterations in calcium-sensing receptor gene transcription via proinflammatory cytokines,
and intracellular accumulation of calcium.21–26 Other less frequent causes of hypocalcemia
in this patient population include acute pancreatitis, massive transfusions and vitamin D
deficiency. Calcium has numerous crucial roles in the cellular function of almost every
system. It is part of signal transduction pathways, contributes to cell membrane potential and
nerve conduction, triggers muscle contraction, is a cofactor of many enzymes and acts as the
second messenger of many hormones that regulate metabolism and gene expression.3,27
Although, it is not yet clear, whether or not the association between hypocalcemia with
higher mortality reflects a cause and effect relationship, the increase from a low iCa along
with improvement in severity of disease, and weakening of mortality hazard ratio by further
adjustment for surrogates of severity (Figure 2, Panel A, model 4 compared to model 3)
Afshinnia et al. Page 6
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
suggest that hypocalcemia itself may be a surrogate for disease severity rather than a
therapeutic target. Carlon et al28 showed no significant improvement in patient
hemodynamic variables with calcium supplementation in sepsis and trauma settings. Several
model systems have also shown worse outcomes with calcium supplementation, and
alleviation of cellular injury with lowering of the extracellular calcium concentration.29–33 A
systematic review of clinical trials reveals that no randomized controlled clinical trial has
ever evaluated the effect of calcium supplementation on mortality, multiple organ
dysfunction, length of stay in the ICU or hospital.34 In spite of that, given the crucial role of
calcium in metabolism and cellular function, recommendations have been made in favor of
supplementation to normalize the serum calcium in critically ill patients.19,21 However,
there is absolutely no evidence to suggest that within physiologic range any level of serum
iCa is associated with a better outcome. Given the lack of clinical trial evidence for a
beneficial effect of calcium supplementation on outcomes within physiologic and normal
limits, the intensity of calcium supplementation to target a pre-defined high-normal or high
level of iCa remains speculative.
Subgroup analysis revealed a consistent pattern of higher mortality risk in the lowest
category of iCa as compared to the highest category for most subgroups. The subgroup
exceptions were likely attributable to insufficient statistical power (for black race and other
races) as well as to the potential impact of additional comorbidities acting as competing risk
factors for death even at higher levels of iCa in younger patients and in those with less
severe illness such as the subgroups with total SOFA<15, CCFARF<13, and Charlson<4.
This study has several strengths. This is the second largest multicenter study of the
relationship between iCa and short term mortality and the analyses of main outcomes had
sufficient power. It also has highly accurate ascertainment of outcomes due to the clinical
trial origins of the study.13 Collection of severity of illness by multiple scoring systems as
well as comorbid conditions at baseline provided a unique opportunity to test the effect of
iCa after extensive adjustment for the most important prognostic variables. This study also
has several important limitations. Although this is a secondary analysis of a well-designed
clinical trial, it was not primarily designed to assess the effect of different levels of iCa
during the ICU stay on the outcomes. As a consequence, serum iCa was not measured
uniformly or consistently for everybody. Comparison of patients with and without iCa
measurement shows that the former group was sicker overall and had higher mortality
compared to the latter group (55.7% vs, 47.7%; supplement Table 7). Thus, differences in
patterns of measurement between patients may have introduced ascertainment bias,
characterized by a higher likelihood of measuring iCa in patients with more severe illness
with a magnitude corresponding to 7% higher mortality in the measurement group, and a
direction toward the sicker patients. However, as the median number of iCa measurements
was identical in all categories of baseline iCa (n=4, P=0.767), the patients’ characteristics
and outcomes were not significantly different by these categories, and as the differences in
risk of mortality manifested with follow up, we infer that the association of iCa with
mortality has not been impacted by ascertainment bias, and although the iCa measurements
were not protocol based, evidence for their randomness argues in favor of unbiased
estimations and therefore the derived conclusions. There were also up to 15% missing in a
few of the baseline covariates posing a significant attrition in sample size in multivariable
Afshinnia et al. Page 7
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
models without imputation. However, as the results of survival models with and without
imputation were not significantly different, we chose to apply the dataset after imputation.
Another limitation is presumption of constancy of last measurement for subsequent
unmeasured iCa with the “last observation carried-forward” method in Cox survival models
which may not be true in every individual case and may have overestimated the effect of
hypocalcemia in some patients who have had a rapid correction. In another approach,
application of time-weighted averaged values between subsequent measures was an
alternative approach which has eliminated the effect of constancy of the pre-missing-value
measurements. As the results from the two approaches were similar, we infer that on
average the method of handling unmeasured iCa between subsequent measurements have
not impacted its relationship with mortality. This study is also unable to assess outcomes in
the hypercalcemic range because of the low prevalence of hypercalcemia. This study is
neither designed nor aimed to identify the impact of calcium supplementation on outcome.
Therefore, it cannot be inferred from the data how much calcium supplementation was used
for each patient. We believe that the safety and efficacy of calcium supplementation on hard
outcomes are best determined by randomized controlled clinical trials, but even in such trials
serum iCa can be and should be used as a reasonable monitoring index to separate arms of
the trials targeting different ranges of serum iCa using different intensities of calcium
supplementation. In this context this study which aimed testing the effect of different ranges
of serum iCa on the defined outcomes has successfully reached to its aims, irrespective of
how the level was achieved.
Conclusion
Cox survival models as well as analysis of time-averaged iCa with use of logistic regression
models suggested that hypocalcemia with iCa < 1.0 mmol/L was independent predictor of
higher mortality in critically ill patients with acute renal failure in need of renal replacement
therapy in the studied cohort. There is no evidence to suggest that above this level, different
values of iCa are necessarily associated with better outcome including better survival,
shorter ICU or hospital stay, better preservation of blood pressure independent of pressor
support, or a higher rate of renal recovery. Randomized controlled clinical trials are needed
to confirm the independent beneficial effect of calcium supplementation as well as to
determine the optimal serum iCa target in critically ill patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
• The ATN Study was conducted by the ATN Investigators and supported by the Cooperative StudiesProgram of the Department of Veterans Affairs Office of Research and Development (VA) and theNIDDK. The data from the ATN study were supplied by the NIDDK Central Repositories. Thismanuscript was not prepared in collaboration with Investigators of the ATN study and does notnecessarily reflect the opinions or views of the ATN study, the VA, the NIDDK Central Repositories, orthe NIDDK. The authors also would like to thank Mallika Kommareddi for her remarks.
• F.A. is supported by grant 5T32DK7378-32.
Afshinnia et al. Page 8
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
References
1. Hill-Eubanks DC, Werner ME, Heppner TJ, Nelson MT. Calcium Signaling in Smooth Muscle.Cold Spring Harb Perspect Biol. 2011; 3:a004549. [PubMed: 21709182]
2. Lang RM, Fellner SK, Neumann A, Bushinsky DA, Borow KM. Left ventricular contractility variesdirectly with blood ionized calcium. Ann Intern Med. 1988; 108:524–529. [PubMed: 3248127]
3. Smith JB. Calcium homeostasis in smooth muscle cells. New Horiz. 1996; 4:2–18. [PubMed:8689272]
4. Maynard JC, Cruz C, Kleerekoper M, Levin NW. Blood pressure response to changes in serumionized calcium during hemodialysis. Ann Intern Med. 1986; 104:358–361. [PubMed: 3946979]
5. Henrich WL, Hunt JM, Nixon JV. Increased ionized calcium and left ventricular contractility duringhemodialysis. N Engl J Med. 1984; 310:19–23. [PubMed: 6689735]
6. Kramer W, Wizemann V, Thormann J, Bechthold A, Schutterle G, Lasch HG. Mechanisms ofaltered myocardial contractility during hemodialysis: importance of changes in the ionized calciumto plasma potassium ratio. Klin Wochenschr. 1985; 63:272–278. [PubMed: 3990169]
7. Chaudhuri TK, Chaudhuri Tu H. Calcium phosphate colloid: possible nidus for metastaticcalcification in hypercalcemia. JAMA. 1972; 222:1061. [PubMed: 4678952]
8. Hartman TE, Muller NL, Primack SL, et al. Metastatic pulmonary calcification in patients withhypercalcemia: findings on chest radiographs and CT scans. AJR Am J Roentgenol. 1994; 162:799–802. [PubMed: 8140993]
9. Kerr DN. Hypercalcemia and metastatic calcification. Cardiovasc Res. 1997; 36:293–297. [PubMed:9534848]
10. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth musclecell matrix mineralization in vitro. Kidney Int. 2004; 66:2293–2299. [PubMed: 15569318]
11. Caruana RJ, Buckalew VM Jr. The syndrome of distal (type 1) renal tubular acidosis. Clinical andlaboratory findings in 58 cases. Medicine (Baltimore). 1988; 67:84–99. [PubMed: 3127650]
12. Kiewiet RM, Ponssen HH, Janssens EN, Fels PW. Ventricular fibrillation in hypercalcaemic crisisdue to primary hyperparathyroidism. Neth J Med. 2004; 62:94–96. [PubMed: 15209475]
13. Palevsky PM, Zhang JH, O'Connor TZ, et al. Intensity of renal support in critically ill patients withacute kidney injury. N Engl J Med. 2008; 359:7–20. [PubMed: 18492867]
14. Palevsky PM, O'Connor T, Zhang JH, Star RA, Smith MW. Design of the VA/NIH Acute RenalFailure Trial Network (ATN) Study: intensive versus conventional renal support in acute renalfailure. Clin Trials. 2005; 2:423–435. [PubMed: 16317811]
15. Egi M, Kim I, Nichol A, et al. Ionized calcium concentration and outcome in critical illness. CritCare Med. 2011; 39:314–321. [PubMed: 21099425]
16. Demirjian S, Chertow GM, Zhang JH, et al. Model to predict mortality in critically ill adults withacute kidney injury. Clin J Am Soc Nephrol. 6:2114–2120. [PubMed: 21896828]
17. Chernow B, Zaloga G, McFadden E, et al. Hypocalcemia in critically ill patients. Crit Care Med.1982; 10:848–851. [PubMed: 7140332]
18. Desai TK, Carlson RW, Geheb MA. Prevalence and clinical implications of hypocalcemia inacutely ill patients in a medical intensive care setting. Am J Med. 1988; 84:209–214. [PubMed:3407650]
19. Zivin JR, Gooley T, Zager RA, Ryan MJ. Hypocalcemia: a pervasive metabolic abnormality in thecritically ill. Am J Kidney Dis. 2001; 37:689–698. [PubMed: 11273867]
20. Hastbacka J, Pettila V. Prevalence and predictive value of ionized hypocalcemia among criticallyill patients. Acta Anaesthesiol Scand. 2003; 47:1264–1269. [PubMed: 14616325]
21. Burchard KW, Gann DS, Colliton J, Forster J. Ionized calcium, parathormone, and mortality incritically ill surgical patients. Ann Surg. 1990; 212:543–549. discussion 9–50. [PubMed: 2222019]
22. Carlstedt F, Lind L, Rastad J, Stjernstrom H, Wide L, Ljunghall S. Parathyroid hormone andionized calcium levels are related to the severity of illness and survival in critically ill patients. EurJ Clin Invest. 1998; 28:898–903. [PubMed: 9824432]
Afshinnia et al. Page 9
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
23. Aderka D, Schwartz D, Dan M, Levo Y. Bacteremic hypocalcemia. A comparison between thecalcium levels of bacteremic and nonbacteremic patients with infection. Arch Intern Med. 1987;147:232–236. [PubMed: 3545115]
24. Taylor B, Sibbald WJ, Edmonds MW, Holliday RL, Williams C. Ionized hypocalcemia in criticallyill patients with sepsis. Can J Surg. 1978; 21:429–433. [PubMed: 719567]
25. Zaloga GP, Chernow B. The multifactorial basis for hypocalcemia during sepsis. Studies of theparathyroid hormone-vitamin D axis. Ann Intern Med. 1987; 107:36–41. [PubMed: 3592447]
26. Song SK, Karl IE, Ackerman JJ, Hotchkiss RS. Increased intracellular Ca2+: a critical link in thepathophysiology of sepsis? Proc Natl Acad Sci U S A. 1993; 90:3933–3937. [PubMed: 8483913]
27. Kelly A, Levine MA. Hypocalcemia in the Critically Ill patient. J Intensive Care Med. 2013;28:166–177. [PubMed: 21841146]
28. Carlon GC, Howland WS, Kahn RC, Schweizer O. Calcium chloride administration innormocalcemic critically ill patients. Crit Care Med. 1980; 8:209–212. [PubMed: 6987039]
29. Liu W, Matsumori A. Calcium channel blockers and modulation of innate immunity. Curr OpinInfect Dis. 24:254–258. [PubMed: 21467929]
30. Carlstedt F, Eriksson M, Kiiski R, Larsson A, Lind L. Hypocalcemia during porcine endotoxemicshock: effects of calcium administration. Crit Care Med. 2000; 28:2909–2914. [PubMed:10966270]
31. Matsuda S. Protective effects of calcium antagonist (nitrendipine) on calcium ionophore A23187-induced liver cell injury. Bull Tokyo Med Dent Univ. 1991; 38:35–44. [PubMed: 1934200]
32. Steinhorn DM, Sweeney MF, Layman LK. Pharmacodynamic response to ionized calcium duringacute sepsis. Crit Care Med. 1990; 18:851–857. [PubMed: 2379399]
33. Li GY, Fan B, Zheng YC. Calcium overload is a critical step in programmed necrosis of ARPE-19cells induced by high-concentration HO. Biomed Environ Sci. 23:371–377. [PubMed: 21112485]
34. Forsythe RM, Wessel CB, Billiar TR, Angus DC, Rosengart MR. Parenteral calcium for intensivecare unit patients. Cochrane Database Syst Rev. 2008; 4 CD006163.
Afshinnia et al. Page 10
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Key Messages
• Outcomes of 60-day all-cause mortality, renal recovery, days free from ICU,
days free from hospital and MAP during ICU stay in mild hypocalcemia (iCa of
1.0 to 1.14 mmol/L) were not different from normocalcemia (iCa≥1.15 mmol/L)
in critically ill patients with AKI needing renal replacement therapy.
• Outcomes of renal recovery, days free from ICU, days free from hospital, and
MAP during ICU stay in severe hypocalcemia (iCa<1.0 mmol/L) were not
different from normocalcemia (iCa≥1.15 mmol/L) in critically ill patients with
AKI needing renal replacement therapy.
• Severe hypocalcemia (iCa<1.0 mmol/L) appeared an independent predictor of
60-day all-cause mortality as compared to normocalcemia in critically ill
patients with AKI needing renal replacement therapy.
• Hypocalcemia may be a surrogate marker for severity of illness and not
necessarily a therapeutic target.
• Randomized controlled clinical trials are needed to determine the optimum level
of serum iCa and optimal supplementation in critically ill patients.
Afshinnia et al. Page 11
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Figure 1.Change of mean ionized calcium ± standard error during course of stay in ICU by categories
of baseline ionized calcium (mmol/L). Number of measurements per category per day is
shown in the table.
Afshinnia et al. Page 12
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Figure 2.Hazard ratio (95% confidence interval) of mortality and renal recovery outcomes:
Model 1: Unadjusted, using categories of baseline ionized calcium, Model 2: Unadjusted,
using ionized calcium as a time-varying variable, Model 3: Model 2, plus gender, race, and
baseline elements of ATN study predictive risk model for 60-day mortality, Model 4: Model
3, plus “mechanical ventilation, mean arterial pressure, number of pressor agents per day,
and SOFA system (coagulation, cardiovascular, liver, central nervous system, respiratory)
during ICU stay” all as time-varying covariates.
Afshinnia et al. Page 13
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Figure 3.Hazard ratio of all-cause mortality in ionized calcium < 1 mmol/L compared to ionized
calcium ≥ 1.15 mmol/L by subgroups of patient’s characteristics and baseline study
variables, according to fully adjusted model (model 4)
Afshinnia et al. Page 14
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Afshinnia et al. Page 15
Table 1
Comparison of baseline characteristics in patients with acute kidney injury by level of baseline ionized serum
calcium, using analysis of variance with Bonferroni post hoc analysis for multiple comparisons
Variables < 1 mmol/L,n=186
1–1.14 mmol/L,n=343
≥ 1.15 mmol/L,n=156
Age (yrs) 57.7 ± 15.7 60.7 ± 15.0 61.3 ± 14.4
Sex
Male (%) 138 (74.2) 256 (74.6) 108 (69.2)
Female (%) 48 (25.8) 87 (25.4) 48 (30.8)
Race
White (%) 134 (72.0) 256 (74.6) 122 (78.2)
Black (%) 29 (15.6) 52 (15.2) 16 (10.3)
Others (%) 23 (12.7) 35 (10.2) 18 (11.5)
Post-open surgical AKI (%) * 69 (37.1) 193 (56.3) 98 (62.8)
Cause of AKI
Ischemic ATN (%) 151 (81.2) 281 (81.9) 136 (87.2)
Nephrotoxic ATN (%) * 32 (17.2) 103 (30.0) 37 (23.7)
Septic ATN (%) 105 (56.5) 168 (49.0) 62 (39.7)
Multifactorial ATN 111 (59.7) 194 (56.6) 83 (53.2)
Mechanical Ventilation (%) 160 (86.0) 280 (81.6) 131 (84.0)
MAP (mmHg) 74.4 ± 16.3 74.6 ± 15.0 76.3 ± 13.8
Baseline SOFA
Respiratory 2.5 ± 1.1 2.5 ± 1.1 2.2 ± 1.1
Coagulation 1.4 ± 1.1 1.4 ± 1.2 1.4 ± 1.2
Liver 1.6 ± 1.3 1.5 ± 1.3 1.6 ± 1.4
Cardiovascular * 2.8 ± 1.6 2.4 ± 1.7 2.2 ± 1.7
Central nervous system 2.7 ± 1.4 2.7 ± 1.4 2.4 ± 1.4
Age adjusted Charlson score! 4.0 ± 3.4 4.3 ± 2.7 4.3 ± 2.6
APACHE II score! 27.9 ± 7.6 26.6 ± 7.3 25.9 ± 7.2
Cleveland Clinic ICU Score! 12.5 ± 3.4 12.3 ± 3.2 12.3 ± 3.2
Pressor support
Epinephrine (%) 12 (6.5) 35 (10.2) 22 (14.1)
Norepinephrine (%) 98 (52.7) 155 (45.2) 63 (40.4)
Phenylephrine (%) 22 (11.8) 35 (10.2) 15 (9.6)
Dopamine (%) 23 (12.4) 54 (15.7) 18 (11.5)
Dobutamine (%) 22 (11.8) 32 (9.3) 13 (8.3)
Vasopressine (%) 51 (27.4) 60 (17.5) 30 (19.2)
Other pressors (%) 1 (0.5) 15 (4.4) 10 (6.4)
*p<0.01;
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Afshinnia et al. Page 16
!Sample size from the first to the third categories of ionized calcium for Charlson score is 163,322, 136; for APACHE score 177, 326, 149, and for
Cleveland score it is 153, 293, and 122, respectively.
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Afshinnia et al. Page 17
Table 2
Management of renal replacement therapy by levels of ionized serum calcium
Variables < 1 mmol/L 1–1.14 mmol/L ≥ 1.15 mmol/L
Intermittent Hemodialysis (IHD)
Treatment provided (no.) 784 1311 761
Days of therapy (no./patient) 8.0 ± 6.3 7.0 ± 5.9 8.0 ± 6.7
Duration of session (hr) 4 ± 1 4 ± 1 4 ± 2
Blood flow (mL/min) 365 ± 61 351 ± 60 357 ± 61
Dialysate flow (mL/min) 738 ± 113 693 ± 139 697 ± 134
Net ultrafiltration (liters/treatment) 1.7 ± 1.3 1.9 ± 1.3 1.7 ± 1.3
Predialysis BUN (mg/dL) 55 ± 29 57 ± 31 53 ± 30
Postdialysis BUN (mg/dL) 19 ± 13 21 ± 15 18 ± 13
Anticoagulant
None (%) 485 (62.8) 961 (73.6) 514 (68.1)
Heparin (%) 249 (32.2) 310 (23.8) 195 (25.8)
Others (%) 38 (5.0) 33 (2.6) 46 (6.1)
KT/Vurea
First treatment 1.11 ± 0.31 1.04 ± 0.29 1.15 ± 0.39
Subsequent treatments 1.30 ± 0.20 1.22 ± 0.29 1.30 ± 0.21
Percentage of therapies by IHD 40.0 ± 35.1 44.2 ± 39.0 43.3 ± 40.0
Continuous venovenous hemodiafiltration
Treatment provided (no.) 999 1901 1084
Days of therapy (no./patient) 6.4 ± 5.6 7.4 ± 6.1 8.8 ± 7.1
Daily duration of therapy/patient (hr) 17.6 ± 6.7 18.0 ± 6.7 18.0 ± 6.8
Blood flow (mL/min) 141 ± 32 143 ± 42 150 ± 36
Dialysate flow (mL/hr) 1134 ± 453 1091 ± 430 1177 ± 387
Replacement flow (mL/hr) 1145 ± 375 1094 ± 407 1130 ± 364
Net ultrafiltration (mL/hr)# 100 [17, 215] 110 [33, 201] 100 [18, 185]
24-hr effluent volume (Liters) 41 ± 21 41 ± 21 42 ± 20
Mean daily BUN (mg/dL) 42 ± 23 44 ± 23 40 ± 23
Effluent flow
Prescribed (mL/kg/hr) 29.6 ± 8.1 28.4 ± 8.0 29.5 ± 8.4
Delivered (mL/kg/hr) 29.7 ± 9.0 29.7 ± 8.9 29.8 ± 9.4
Anticoagulant
None (%) 72 (51.4) 272 (64.3) 323 (66.5)
Heparin (%) 54 (38.6) 87 (20.3) 85 (17.5)
Citrate (%) 14 (10.0) 55 (12.8) 20 (4.1)
Others (%) 3 (2.3) 15 (3.5) 58 (11.9)
Percentage of therapies by CVVHDF 56.6 ± 37.6 52.9 ± 40.3 55.7 ± 40.6
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Afshinnia et al. Page 18
Variables < 1 mmol/L 1–1.14 mmol/L ≥ 1.15 mmol/L
Sustained Low-efficiency dialysis
Treatments provided (no.) 62 92 23
Days of therapy (no./patient) 5.2 ± 4.4 4.8 ± 5.1 2.8 ± 2.9
Duration of session (hr) 8 ± 2 8± 4 10 ± 4
Blood flow (mL/min) 200 ± 0 226 ± 50 204 ± 30
Dialysate flow (mL/min) 252 ± 90 249 ± 124 230 ± 88
Net ultrafiltration (liters/treatment) 1.9 ± 1.6 1.4 ± 1.4 1.2 ± 1.1
Anticoagulant
None (%) 41 (66.1) 70 (76.9) 16 (76.2)
Heparin (%) 21 (33.9) 15 (16.5) 2 (9.5)
Others (%) 0 (0) 6 (6.6) 3 (14.3)
Percentage of therapies by SLED 3.4 ± 14.2 2.9 ± 14.4 1.0 ± 8.3
Isolated ultrafiltration
Treatments provided (no.) 28 50 39
Net ultrafiltration (Liters/treatment) 2.6 ± 1.4 2.5 ± 1.0 2.6 ± 1.0
#Median [Interquartile range]
Ren Fail. Author manuscript; available in PMC 2014 November 01.
NIH
-PA
Author M
anuscriptN
IH-P
A A
uthor Manuscript
NIH
-PA
Author M
anuscript
Afshinnia et al. Page 19
Table 3
Comparison of primary and secondary outcomes by base-line ionized calcium using analysis of variance with
Tukey post hoc correction for multiple comparisons; values are count (percentage) or mean ± standard error.
Variables < 1 mmol/L,n=186
1–1.14 mmol/L,n=343
≥ 1.15 mmol/L,n=156
Sixty-day mortality (%) 106 (57.0) 188 (54.8) 85 (54.5)
Renal recovery in survivors to day 28 (%)* 38 (39.6) 76 (41.5) 37 (43.0)
Days free from ICU by day 60 (days) 17 ± 1.6 19 ± 1.2 19 ± 1.8
Days free from hospital by day 60 (days) 10 ± 1.2 12 ± 1.0 12 ± 1.5
*Sample size in the first to the third category of ionized calcium for renal recovery is 109, 151, and 61, respectively.
Ren Fail. Author manuscript; available in PMC 2014 November 01.